359 related articles for article (PubMed ID: 19046111)
1. Maintenance treatment in metastatic breast cancer.
Sánchez-Muñoz A; Pérez-Ruiz E; Ribelles N; Márquez A; Alba E
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1907-12. PubMed ID: 19046111
[TBL] [Abstract][Full Text] [Related]
2. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
4. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Gligorov J; Lotz JP
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
[TBL] [Abstract][Full Text] [Related]
5. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
[TBL] [Abstract][Full Text] [Related]
6. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
Pandya KJ; Hu P; Osborne CK; Falkson G; Tormey DC;
Am J Clin Oncol; 2007 Apr; 30(2):113-25. PubMed ID: 17414459
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy for metastatic breast cancer].
Schmid P; Possinger K
Zentralbl Gynakol; 2006 Dec; 128(6):318-26. PubMed ID: 17213969
[TBL] [Abstract][Full Text] [Related]
8. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
9. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
[TBL] [Abstract][Full Text] [Related]
10. First-line chemotherapy for metastatic breast cancer.
Telli ML; Carlson RW
Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S66-72. PubMed ID: 19596645
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of advanced breast cancer.
Szántó J
Acta Med Hung; 1994; 50(3-4):185-93. PubMed ID: 8587832
[TBL] [Abstract][Full Text] [Related]
12. The use of chemotherapy in metastatic breast cancer.
Garber JE; Henderson IC
Hematol Oncol Clin North Am; 1989 Dec; 3(4):807-21. PubMed ID: 2481671
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of metastatic breast cancer].
Eidtmann H; Jonat W
Ther Umsch; 1993 May; 50(5):352-8. PubMed ID: 7690992
[TBL] [Abstract][Full Text] [Related]
15. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
16. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.
Dufresne A; Pivot X; Tournigand C; Facchini T; Altweegg T; Chaigneau L; De Gramont A
Breast Cancer Res Treat; 2008 Jan; 107(2):275-9. PubMed ID: 17380382
[TBL] [Abstract][Full Text] [Related]
17. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.
Coudert B; Focan C; Genet D; Giacchetti S; Cvickovic F; Zambelli A; Fillet G; Chollet P; Amoroso D; Van Der Auwera J; Lentz MA; Marreaud S; Baron B; Gorlia T; Biville F; Lévi F
Chronobiol Int; 2008 Sep; 25(5):680-96. PubMed ID: 18780198
[TBL] [Abstract][Full Text] [Related]
18. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.
O'Neil BH; Goldberg RM
Oncologist; 2008 Oct; 13(10):1074-83. PubMed ID: 18922828
[TBL] [Abstract][Full Text] [Related]
19. [High-dose chemotherapy for metastatic breast cancer].
Lalle M; De Rosa L; Perillo A; Scambia G; D'Aprile M; Antimi M
Clin Ter; 2004; 155(7-8):305-15. PubMed ID: 15553258
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of cancer of the breast in the metastatic phase].
Clavel M; Biron P; Chauvin F; Guastalla JP; Rebattu P; el Foudeh M
Bull Cancer; 1989; 76(1):75-85. PubMed ID: 2653473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
